NEW YORK (Reuters Health) Jul 01 –
In patients with advanced non-small-cell lung cancer (NSCLC), treatment with paclitaxel/carboplatin-based regimens is associated with improved survival compared that achieved with cisplatin-based regimens, according to a recent report.
Dr. John D. Hainsworth, from The Sarah Cannon Cancer Center in Nashville, Tennessee, and colleagues assessed the outcomes of 321 patients with advanced NSCLC who were treated with one of three paclitaxel/carboplatin-based regimens between March 1995 and 1998. The outcomes of these patients were retrospectively compared to those of similar patients who had received supportive care only or cisplatin-based regimens.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!